Daniel Rӧshammar is the Director of SGS Exprimo. Daniel obtained a M.Sc. in Pharmaceutical Sciences in 2003 followed by a postgraduate Master’s program in clinical drug development (2003-2004) at Uppsala University, Sweden. After studying quantitative clinical pharmacology aspects of antiretroviral therapies, he received his PhD in Medical Sciences in 2009 from the Sahlgrenska Academy at Gothenburg University, Sweden.
Daniel has had various expert and managing positions in the pharmaceutical industry at AstraZeneca, Sweden (2009-2013, 2014-2016) and at Ferring Pharmaceuticals, Denmark (2013-2014), including an internship at Servier, France (2002-2003). He has worked across a range of therapeutic areas (infectious diseases, cardiovascular, respiratory, urology, oncology, intensive care, and reproductive health) and he has also contributed to the filing and subsequent approval of new drug applications.
Daniel has successfully supervised 2 PhD students (Gothenburg University, Sweden and Roskilde University, Denmark). He is especially passionate about how modeling and simulation can inform the design and evaluation of clinical studies at all stages of development and how it may add value to the decision making process in an easy communicable way.
Daniel joined Exprimo in 2016 and lives outside of Gothenburg, Sweden.